뇌종양 치료제 시장 : 적응증, 약제 클래스별, 투여 경로, 치료법, 약제 유형, 최종 사용자, 유통 채널별 - 세계 예측(2026-2032년)

The Brain Cancer Drugs Market is projected to grow by USD 4.03 billion at a CAGR of 8.05% by 2032.

Brain cancer drugs are moving from a historically cytotoxic, surgery-adjuvant model toward biomarker-guided oncology that combines alkylating agents, targeted therapies, immuno-oncology, tumor treating fields, radiopharmaceutical concepts, and precision trial designs. Glioblastoma remains the most aggressive primary malignant brain tumor in adults, while pediatric and lower-grade gliomas increasingly require molecular stratification to guide therapy selection.

The commercial and clinical focus is being shaped by high unmet need, limited blood-brain barrier penetration, tumor heterogeneity, and recurrence after standard-of-care therapy. Verified regulatory milestones underscore the shift: temozolomide remains central in newly diagnosed glioblastoma, tumor treating fields are FDA-authorized for glioblastoma, targeted combinations such as dabrafenib plus trametinib have expanded options for BRAF V600E-mutant glioma, and vorasidenib received FDA approval in 2024 for IDH-mutant grade 2 astrocytoma or oligodendroglioma after surgery.

Transformative Shifts in the Brain Cancer Drug Landscape

The brain cancer drugs landscape is being transformed by molecular diagnostics, adaptive clinical trials, and therapies designed around tumor biology rather than histology alone. The 2021 WHO Classification of Tumors of the Central Nervous System reinforced the importance of IDH mutation, 1p/19q codeletion, H3 K27 alterations, MGMT promoter methylation, and other markers in diagnosis and treatment planning.

Drug developers are prioritizing blood-brain barrier optimization, central nervous system pharmacokinetics, and combination regimens that can overcome immune suppression in the tumor microenvironment. The market is also seeing renewed interest in peptide vaccines, oncolytic viruses, checkpoint combinations, antibody-drug conjugates, PARP inhibitors, IDH inhibitors, and radiotherapy-sensitizing approaches, supported by growing genomic testing adoption in major oncology centers.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across discovery, diagnosis, trial design, and treatment monitoring in brain cancer drugs. AI-enabled radiomics can help quantify tumor volume, edema, necrosis, pseudoprogression, and treatment response from MRI, while digital pathology models are improving tumor grading support and biomarker interpretation when paired with expert review.

In drug development, machine learning is being used to screen compounds for CNS penetration, predict resistance pathways, identify patient subgroups, and optimize adaptive trial enrollment. Its most immediate value lies in reducing development inefficiency: brain cancer trials often struggle with small eligible populations, rapid progression, and imaging complexity, and AI can improve site selection, eligibility matching, longitudinal response assessment, and real-world evidence generation.

Key Regional Insights

North America leads in brain cancer drug development because of dense neuro-oncology networks, FDA orphan drug incentives, National Cancer Institute-supported research, and strong adoption of molecular testing. The United States remains the anchor market for first launches, while Canada contributes through publicly funded oncology systems, academic trial sites, and structured health technology assessment processes.

Europe benefits from EMA pathways, multinational cooperative research, and strong neuro-oncology centers across Germany, France, Italy, Spain, and the United Kingdom, although reimbursement timing varies by country. Asia-Pacific is expanding quickly as China, Japan, South Korea, Australia, and India strengthen oncology trial infrastructure, genomic medicine adoption, and specialist cancer care. Latin America, led by Brazil and Mexico, is improving access through specialty oncology centers and expanding private-sector diagnostics, while the Middle East shows rising demand in tertiary hospitals and national cancer programs. Africa remains more access-constrained, with availability shaped by neurosurgery capacity, pathology infrastructure, radiotherapy access, specialist availability, and reimbursement coverage.

Key Group Insights

The G7 markets remain highly influential because they combine advanced regulatory systems, reimbursement capacity, academic neuro-oncology expertise, and high participation in pivotal trials. The European Union supports cross-border research collaboration and centralized regulatory review, creating a structured pathway for innovative brain cancer drugs, although health technology assessment outcomes differ by member state. NATO-aligned markets generally benefit from mature health systems, interoperable research ecosystems, and strong academic oncology networks that support trial execution and evidence generation.

BRICS markets are strategically important for future patient access and clinical trial diversification, especially China, India, and Brazil, where cancer diagnostics, oncology infrastructure, and local innovation capacity are expanding. ASEAN is gaining relevance through Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines as specialist oncology services, private hospital networks, and molecular testing access improve. GCC countries are investing in advanced cancer care, national oncology strategies, international hospital partnerships, and medical tourism, creating stronger demand for precision brain cancer therapies in tertiary care settings.

Key Country Insights

The United States is the most active commercialization and research market for brain cancer drugs, supported by FDA expedited programs, orphan drug pathways, comprehensive cancer centers, and strong biotechnology funding. Canada provides high-quality trial participation, provincial cancer agencies, and structured public reimbursement review. Mexico and Brazil are important Latin American access markets, with Brazil offering the region's largest oncology base and Mexico benefiting from proximity to North American clinical and regulatory ecosystems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist neuro-oncology care with national reimbursement processes, biomarker testing expansion, and established academic trial networks, while Russia presents a more complex access environment shaped by reimbursement, procurement, and geopolitical constraints. China is scaling domestic oncology innovation, regulatory reform, and brain tumor clinical trials; India has a large patient base and growing precision diagnostics in major metropolitan cancer centers; Japan and South Korea offer sophisticated regulatory systems, advanced imaging, and strong translational research; and Australia is a highly connected clinical trial market with internationally recognized cancer centers and robust neuro-oncology expertise.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-defined development strategies, robust CNS pharmacokinetic evidence, and combination designs that address tumor immune suppression, resistance, and recurrence. Development plans should incorporate MGMT, IDH, BRAF, H3 K27, EGFR alteration, TERT, 1p/19q codeletion, and other relevant markers early in clinical planning to improve patient selection, regulatory alignment, and payer confidence.

Commercial teams should prepare for evidence requirements beyond response rate, including progression-free survival, overall survival, neurocognitive outcomes, steroid-sparing benefit, seizure control, quality of life, and real-world durability. Partnerships with academic neuro-oncology centers, imaging AI vendors, diagnostic laboratories, contract research networks, and patient advocacy groups can accelerate enrollment, strengthen evidence generation, and improve market access readiness across advanced and emerging oncology systems.

Research Methodology

This executive summary is based on secondary research from verified public sources, including regulatory agency announcements, peer-reviewed oncology literature, clinical trial registries, cancer classification standards, treatment guidelines, and publicly available institutional research outputs. The analysis emphasizes data-backed developments such as approved therapies, recognized biomarkers, established standards of care, documented diagnostic trends, and regional access dynamics.

The methodology combines qualitative market assessment, therapeutic landscape review, regulatory tracking, regional access evaluation, and technology trend analysis. Findings were synthesized to support executive content while avoiding unsupported market sizing claims, speculative revenue estimates, market share statements, forecasting, or unverified clinical performance claims.

Conclusion

The brain cancer drugs market is entering a more precise, technology-enabled phase as molecular diagnostics, CNS-optimized therapies, and AI-supported development reshape the treatment pathway. Despite persistent challenges in glioblastoma and recurrent disease, recent targeted therapy approvals and biomarker-led trial designs show that clinically meaningful progress is accelerating.

Organizations that align discovery, clinical development, diagnostics, regulatory strategy, and market access will be best positioned to compete. The strongest opportunities will emerge where therapeutic innovation is paired with validated biomarkers, measurable patient outcomes, rigorous evidence generation, and equitable access across advanced and emerging oncology systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Cancer Drugs Market, by Indication

• 7.1. Glioblastoma Multiforme
• 7.2. Meningioma
• 7.3. Metastatic Brain Tumors
• 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Drug Class

• 8.1. Chemotherapy
  • 8.1.1. Alkylating Agents
  • 8.1.2. Antimetabolites
  • 8.1.3. Plant Alkaloids
• 8.2. Immunotherapy
  • 8.2.1. Cancer Vaccines
  • 8.2.2. CAR-T Therapy
  • 8.2.3. Checkpoint Inhibitors
• 8.3. Supportive Therapy
  • 8.3.1. Anti-Emetics
  • 8.3.2. Growth Factors
• 8.4. Targeted Therapy
  • 8.4.1. Monoclonal Antibodies
  • 8.4.2. Tyrosine Kinase Inhibitors

9. Brain Cancer Drugs Market, by Route Of Administration

• 9.1. Intrathecal
• 9.2. Intravenous
• 9.3. Oral

10. Brain Cancer Drugs Market, by Treatment Modality

• 10.1. Monotherapy
• 10.2. Combination Therapy

11. Brain Cancer Drugs Market, by Drug Type

• 11.1. Branded
• 11.2. Generic

12. Brain Cancer Drugs Market, by End User

• 12.1. Clinics
• 12.2. Home Healthcare
• 12.3. Hospitals

13. Brain Cancer Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacies
• 13.2. Online Pharmacies
• 13.3. Retail Pharmacies

14. Brain Cancer Drugs Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Brain Cancer Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Brain Cancer Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. AbbVie Inc.
• 18.2. Amgen Inc.
• 18.3. Amneal Pharmaceuticals, Inc.
• 18.4. Arbor Pharmaceuticals, LLC
• 18.5. AstraZeneca PLC
• 18.6. Bayer AG
• 18.7. Bristol-Myers Squibb Company
• 18.8. Chimerix, Inc.
• 18.9. Day One Biopharmaceuticals, Inc.
• 18.10. DNAtrix, Inc.
• 18.11. Eisai Co., Ltd.
• 18.12. Eli Lilly and Company
• 18.13. Emcure Pharmaceuticals Limited
• 18.14. F. Hoffmann-La Roche Ltd
• 18.15. GlaxoSmithKline plc
• 18.16. Ipsen SA
• 18.17. Johnson & Johnson
• 18.18. Karyopharm Therapeutics Inc.
• 18.19. Kazia Therapeutics Limited
• 18.20. Merck & Co., Inc.
• 18.21. Merck KGaA
• 18.22. NextSource Pharmaceuticals, LLC
• 18.23. Novartis AG
• 18.24. Novocure GmbH
• 18.25. Pfizer Inc.
• 18.26. Servier Pharmaceuticals LLC
• 18.27. Sumitomo Pharma Co., Ltd.
• 18.28. Sun Pharmaceutical Industries Limited
• 18.29. Takeda Pharmaceutical Company Limited
• 18.30. Teva Pharmaceutical Industries Ltd.